Barbara Faganel Kotnik, Janez Jazbec, Petra Bohanec Grabar, Cristina Rodriguez-Antona and Vita Dolzan
Tanigawara Y Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acutelymphoblasticleukemia or lymphoma J Pediatr Hematol Oncol 2008 30 347 52 10.1097/MPH.0b013e318165b25d
15 Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dolžan V, Jazbec J. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acutelymphoblasticleukaemia and malignant lymphoma. Eur J Clin Pharmacol 2011; 67 : 993-1006. 10.1007/s00228-011-1046-z Faganel Kotnik
1. Kaste SC, Goodman P, Leisenring W. Impact of Radiation and Chemotherapy on Risk of Dental Abnormalities: A Report from the Childhood Cancer Survivor Study. Cancer. 2009;115:5817-5827.
2. Welbury RR, Craft AW, Murray JJ, Kernahan J. Dental health of survivors of malignant disease. Arch Dis Child. 1984;59:1186-1187.
3. Kaste SC, Hopkins KP, Jones D, Crorn D, Greenwald CA, Santana VW. Dental abnormalities in children treated for acutelymphoblasticleukemia. Leukemia. 1997
Luidmyla F. Kaskova, Nataliia V. Yanko and Irena Y. Vashchenko
analysis and periodontal status in children with atopy. I nterv Med Appl Sci. 2017;9(4):199-203.
5. Arigbede AO, Babatope BO, Bamidele MK: Periodontitis and systemic diseases: A literature review. J Indian Soc Periodontol. 2012;16(4):487-91.
6. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ et al. Improved survival for children and adolescents with acutelymphoblasticleukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30(14):1663-69.
7. Lauritano D, Petruzzi M, Fumagalli T, Giacomello MS
Elena Andrus, Anca Nicolescu, H. Bumbea and Ana-Maria Vlădăreanu
We present the case of a 71-year-old woman diagnosed with chronic lymphocytic leukemia who received multiple chemotherapeutic lines and evolved to acute lymphoblastic leukemia. The patient was Rai stage 0 at the time of the diagnosis and was monitored for almost 9 years. After that, the disease progressed and the patient began chemotherapy (fludarabine/cyclophosphamide combination), obtained complete remission and relapsed one year later after finishing treatment. She received multiple therapeutic regimens, accompanied by multiple infectious complications. After 8 years of evolution since she started chemotherapy, bone marrow aspirate and immunophenotyping revealed acute lymphoblastic leukemia. The occurrence of acute leukemia in CLL is rare and may arise from the same clone; however, most cases appear after patients have received chemotherapy, suggesting that they are therapy-related.
Ruxandra Irimia, Ioana Teodora Tofolean, Roxana Gabriela Sandu, Oana Elena Băran, Maria Cătălina Ceauşescu, Vlad Coşoreanu, Maria Teodora Ilie, Ramona Babeş, Constanţa Ganea and Irina Băran
Doxorubicin is a widely used chemotherapeutic drug, effective on patients with acute lymphoblastic leukemia but associated with significant long term cardio-toxicity. Menadione (vitamine K3) and the flavonoid quercetin are known as strong apoptogens in human leukemia Jurkat T cells.
We explored the potential synergic cytotoxic effects of doxorubicin in association with quercetin and Menadione in this cellular model for acute lymphoblastic leukemia.
Cellular viability, apoptosis, necrosis oxidative stress and cellular cycle were determined by flow cytometry utilizing Jurkat lymphoblasts labeled with Annexin V-FITC/7-AAD, CM-H2DCFDA/7-AAD and propidium iodide respectively.
Results indicate a dose-dependent oxidative-stress generation, cell cycle arrest and apoptosis induction by doxorubicin alone, correlated with a decrease of the required doses when the anticancer drug was associated with quercetin and menadione, hence supporting the theory of an additive cytotoxic effect on leukemia cells.
Introducing QC-MD combinations in leukemia doxorubicin-based treatment could significantly increase the treatment’s efficacy. The main mechanism responsible for this effect appears to be the increase in DOX affinity for DNA, which enables lowering of the therapeutic dose.
Cristina Marinescu, Ana-Maria Vladareanu and Felicia Mihai
, LAZARUS HM, FRANKLIN IM, LITZOW MR, CIOBANU N, PRENTICE HG, DURRANT J, TALLMAN MS & GOLDSTONE AH. Induction therapy for adults with acutelymphoblasticleukaemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005; 106, 3760-3767.
5. JACOB M ROWE. Prognostic factors in adult acutelymphoblasticleukaemia. British Journal of Haematology, 2010, 150, 389-405.
6. MOORMAN AV, CHILTON L, WILKINSON J, et al. A population-based cytogenetic study of adults with acutelymphoblasticleukemia
review of literature. J Hematol Oncol. 2009; 2(1): 26-31.
3. Atlas of Genetics and Cytogenetics in Oncology and Haematology online, 1998 (http://atlasgeneticsoncol ogy.org/).
4. Bargetzi MJ, Mühlematter D, Tichelli A, Jotterand M, Wernli M. Dicentric translocation (9;12) presenting as refractory Philadelphia chromosomepositive acute B-cell lymphoblastic leukemia. Cancer Genet Cytogenet. 1999; 113(1): 90-92.
5. D’Angelo G, Hotz AM, Todeschin P. Acutelymphoblasticleukemia with hypereosinophilia and 9p21 deletion: case
Hasan A. Burnusuzov, Mariya I. Spasova, Mariana A. Murdjeva, Angelina A. Stoyanova, Ivan N. Mumdziev, Valeriya I. Kaleva, Milena I. Belcheva and Miroslava N. Bosheva
1. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acutelymphoblasticleukaemia and its relationship to other prognostic factors: A Children’s Oncology Group study. Blood 2008;111:5477-85.
2. Campana D. Minimal residual disease monitoring in childhood acutelymphoblasticleukemia. Curr Opin Hematol 2012;19(4):313-8.
3. Bartram CR, Schrauder A, Köhler R, Schrappe M. Acutelymphoblasticleukemia in children. Treatment planning via minimal
Rina Mutiara, Bernadius Agustinus, Christian Badia Sitompul, Amarila Malik, Djajadiman Gatot and Frans D. Suyatna
[ 2 ]. The most common malignancy in the pediatric population worldwide is acutelymphoblasticleukemia (ALL). ALL is a heterogeneous group of leukemias that result from the clonal proliferation of cancerous lymphoblasts in bone marrow, and in secondary lymphoid organs. Children 1–10 years old are at particular risk of developing ALL. The overall cure rate is approximately 80% [ 3 ].
The Indonesian Paediatric Oncology Foundation stated that 2%-3% cancer cases in Indonesia occur in children [ 4 ]. Based on Cipto Mangunkusumo Hospital data from 2000-2006, there were